Shows
AI Agents: Top Trend of 2026 - by AIAgentStore.aiPodGo — Multilingual listen/read audio briefings for commutes and quick learningLearn more about PodGo on AI Agent Store: https://aiagentstore.ai/ai-agent/podgoList of AI Agents from newest Podcast Season 3 (including upcoming episodes): https://aiagentstore.ai/collection/podcast-season-3-hubiknfakzsjList of AI Agents from Podcast Season 2: https://aiagentstore.ai/collection/podcast-season-2-vlnpozxvkssyList of AI Agents from Podcast Season 1: https://aiagentstore.ai/collection/podcast-season-1-ucqthuywrwpdFind more AI Agents: AI Agent Store.AI agents ecosystem view: https://aiagentstore.ai/ecosystem.Biggest AI agents video collection: https://aiagentstore.ai/video.Support the show...
2026-05-2203 min
The Mark Bishop ShowTMBS E396: Zach Steele - Successful Entrepreneur, COO of PodGoZach Steele is the COO and wears many more hats with the new exciting platform for Podcasters.
To support us, podcasters that place their shows on PodGo now attract serious advertisers.
Still in Beta but it advances more and more every day, Podgo.io is the go! Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com
for information about our collection and use of personal data for
advertising.
2026-04-1133 min
2025-09-1010 min
2025-09-0319 min
2025-08-2711 min
2025-08-2013 min
2025-08-1313 min
Best Of Becoming America: The Constitutional Convention of 1787You Are The We - David FerrieroPreservation of our founding documents and records of debates and other commentaries on the purposes and intentions of the Founders are essential to both our past and present application of the Constitution and the Bill of Rights. They are more than memories of the past, they continue to be the foundation upon which our government and liberties rest. In this final episode of Becoming America, David Ferriero, Archivist of the United States, discusses the role of the National Archives in safeguarding the original US Constitution and other founding documents. He explains how the Archives work alongside other government agencies, how...
2025-08-0958 min
The Best Of BioTech IQA Journey From Investment Banker To The CEO Of A Biotech Developing Cancer Therapy With Bryan KobelBryan Kobel decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of TC BioPharm, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how...
2025-08-0750 min
2025-08-0610 min
2025-07-3010 min
2025-07-2311 min
2025-07-1610 min
2025-07-0910 min2025-07-0214 min
2025-06-2512 min
2025-06-1812 min
2025-06-1112 min
2025-06-0410 min
Live SouthernThings You Need To Know Before Moving SouthLots of advice of the dos and don'ts of moving to the south.
2025-05-2819 min
Best Of Becoming America: The Constitutional Convention of 1787Our Sun Is Rising – A Group Of Americans“America is perfect idea; the United States is a work in progress.” This has been a constant theme during our “Becoming America” series. In today's society, more diverse than ever, how do the ideas that motivated our Founders stand up? Does the Constitution still resonate with the people? This episode features everyday Americans sharing their thoughts about the Constitution, which section means the most to them, and what it means to be an American. Tune in as they provide brief individual glimpses of their views of our country's ideas of liberty, opportunity, security and individual freedom.
2023-05-0257 min
Best Of Becoming America: The Constitutional Convention of 1787We, The People - Andrew GuilfordThe Preamble of the Constitution contains its most revolutionary statement, beginning with the remarkable statement that the new government would be based on the authority of “We the People.” In this episode of “Becoming America,” Dr. Jo Ellen Chatham, Judge Jim Gray, and Bijan Kian interview Judge Andrew Guilford. Retired after serving for nearly 14 years as a United States Federal District Court Judge, Judge Guilford is one of only two district judges in his region to have been invited to sit on the Federal Circuit Court of Appeals - the Ninth Circuit. In this episode, he addresses the purpose and history o...
2023-04-2555 min
Best Of Becoming America: The Constitutional Convention of 1787Someone Has Got To Decide – Dr. Gordon LloydFortunately, there are thousands of documents recording the drafting and ratification of our Constitution and the Bill of Rights. Letters, journals, newspaper articles, political pamphlets and much more provide a comprehensive account – including from both sides - those who favored and those who disapproved of the Constitution. Our guest in this episode has been shaping the conversation about our American history through his work with the Ashbrook Center. Dr. Gordon Lloyd is the Robert and Katheryn Dockson Professor of Public Policy at Pepperdine University and the creator of four highly regarded websites on the origin of the Constitution. He joins Dr...
2023-04-1852 min
Best Of Becoming America: The Constitutional Convention of 1787It’s Lonesome At The Top - George WashingtonIt can be lonesome at the top, especially when you lead not only a country but a country at the cusp of transformation. At the creation of the United States, there was one indispensable man. He commanded the Continental Army through the Revolutionary War, presided over the Constitutional Convention, and was elected to be our first President. We all know him. His name George Washington. Dr. Jo Ellen Chatham, Judge Jim Gray, and Bijan Kian have prepared a unique interview for us, diving deep into the insights and experience of the country's first Commander-in-Chief! Why did General Washington believe the Ar...
2023-04-1157 min
Best Of Becoming America: The Constitutional Convention of 1787The Studied Silence – Maj. Gen. James WilliamsWhy did our Founding Fathers ignore the issue of slavery when crafting the Constitution? To understand this better, we need to put everything in context with the times. The incipient federation was at risk of many Southern states not joining if slavery was outlawed, and many of the delegates themselves were slave owners. But to their credit, they did make the institution much less brutal. To help us gain a better understanding of this prominent and often controversial sticking point of American history, Judge Jim Gray, Professor Jo Ellen Chatham, and “The American”, Bijan Kian are joined by Major General Jame...
2023-04-0448 min
The Best Of BioTech IQBiotech Chief People Officer Discusses How To Build Company CultureScience will only get you so far in biotech. No matter how ingenious your products are, you will never succeed as a company if you don’t have all the pieces if business development in place. And there is no greater piece than the people piece. As the Chief People Officer of Biomea Fusion, Naomi Cretcher knows that company culture is what is going to make or break her company’s success. Despite everything that went on with COVID and with a recession looming, Naomi is confident that investing on their talent pool with pay off in terms of company succ...
2022-12-1838 min
The Best Of BioTech IQQualigen Therapeutics: How To Develop An Oncology Therapeutics Pipeline From A CMO's Perspective With Tariq Arshad, MDThere isn’t a cure for cancer yet, but if everyone can come together, we may find that cure sooner rather than later. One biotech company that is trying to solve cancer is Qualigen Therapeutics. With their oncology therapeutics pipeline, they could be onto something with their leading asset QN-302. Join Ammon Rivera as he talks to the Chief Medical Officer of Qualigen Therapeutics, Tariq Arshad, MD, about where they are right now in their therapeutics pipeline. Learn why cancer is the greatest injustice and how Tariq is fighting to stop it. Find out more about their research in Qualigen Therap...
2022-10-2244 min
The Best Of BioTech IQQualigen Therapeutics: How Do You Develop A Successful Therapeutics Pipeline In Oncology With Amy BroidrickQualigen Therapeutics is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the last few years. In this first episode of a three-part series featuring top executives of Qualigen Therapeutics, Ammon interviews Amy Broidrick, the firm’s President and Chief Strategy Officer. She shares what she brings to the table in the company’s transition from a preclinical stage company to a brand new business venture. She also talks about her deep love for market research, her career...
2022-09-1846 min
The Best Of BioTech IQMapping The Human Immune System: Using AI To Change Drug Development With Noam SolomonAI has gone so far as to potentially change drug development, and these developments have the potential to make a difference in people’s lives. On this episode of BioTech IQ, Ammon interviews Noam Solomon, the CEO of Immunai. Immunai is developing an AI platform that leverages big data, single cell multiomics, and machine learning to bridge the gap between casual immunology and translational disease biology. Their platform is mapping the human immune system at an unprecedented level of granularity, allowing them to identify the right targets to go after. In this interview, Noam shares his knowledge on reprogramming the im...
2022-09-0648 min
The Best Of BioTech IQGoing Beyond The Current Standard Of Care For Anxiety, Depression, And CNS Disorders With Shawn SinghSocial anxiety disorder is the third most common mental health disorder. Over 23 million Americans alone are affected by it. This disorder can continue to grow into depression and drug abuse, so it's very important to catch it early so it can be stopped. But how can it be stopped? Shawn Singh, the CEO and Director of VistaGen Therapeutics, and his team are creating a nasal spray to help people with social anxiety disorder. Just like an inhaler for asthma, this nasal spray can do for social anxiety. Join Ammon Rivera as he talks to Shawn Singh about the PH94B n...
2022-07-2246 min
The Best Of BioTech IQHarnessing the Innate Immune System By Developing Three Types of iPSC-Derived Natural Killer Cells With Daniel TeperCompanies in the biotech space are making contributions to help find a cure for cancer. Today’s guest is no exception. In today’s episode, Ammon Rivera sits down with Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology they’re using to develop a treatment for cancer. Daniel discusses how they’ve developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of disruptive innovation coming from the biotech industry. Daniel also discusses how the field is dealing with worsening market conditions...
2022-07-1632 min
The Best Of BioTech IQCell Cycle Therapy: Understanding The Cell Cycle Biology To Treat Cancer With Spiro RombotisCell cycle biology is key to understanding cancer. You have to hit the cancer cells early before they become smart and adapt. There is a stage in the cell cycle called mitosis. This is where, if done right, can cause cancer cells to suicide. This is where the biotech company, Cyclacel comes in with all their research into the cell cycle of cancer. Join Ammon Rivera as he talks to Spiro Rombotis about some of Cyclacel's cell cycle therapies. Spiro is the CEO of Cyclacel. His mission is to use cell cycle biology to treat cancer and other serious diseases...
2022-06-1155 min
The Best Of BioTech IQCan Lineage Cell Therapeutics Proprietary Cell-Based Therapy Platform Change Treatment Development?Have you ever thought about having replacement parts for your body? It sounds like science fiction, but it’s now as real as the eyes you’re using to read this, thanks to cell-based therapy. Brian Culley is one of the leaders in this field. He is the CEO of Lineage Cell Therapeutics, a company developing treatments for multiple indications based on their proprietary cell-based therapy platform. Leveraging in-house manufacturing, they are attacking multiple indications from ophthalmology to immuno-oncology. In this episode, Brian joins Ammon Rivera to explain what their strategy is, where they are currently in the development process, and...
2022-05-2838 minThe Best Of BioTech IQGlobal Tensions And Supply Chains And Their Effect On Biotech. Guillermo Morales, PhD, CEO Of InnoventyxThe biotech industry has been bombarded with disruptions in recent years, from a global pandemic to rising global tensions. How are they dealing with the supply chain issues and how else has it impacted the industry? In this episode, Ammon Rivera sits down with two-peat guest, Guillermo Morales, PhD, CEO of Innoventyx. Guillermo makes us privy to the issues brought on by COVID-19 and the geopolitical tensions such as the Russia-Ukraine conflict. He also discusses intellectual property in greater depth and why it’s important to act fast when patenting your product. Moving from Latin America to the United States, Gu...
2022-05-1853 min
The Best Of BioTech IQCan Hepion Pharmaceuticals Develop the First Treatment Approved For NASH? With Robert Foster, Pharm D, PhDOn this episode of BioTech IQ, Ammon Rivera interviews Robert Foster Pharm D, PhD, CEO of Hepion Pharmaceuticals. Robert brings 30 years of experience to this discussion and shares with us details of his background that led him to where he is today. We also discuss Hepion Pharmacetuicals current clinical trials to development treatments targeting chronic liver diseases including NASH, cancer, and chronic hepatitis virus infection. A quarter of the people in the US have fatty livers and of those, about a fifth will likely develop NASH. It’s a big problem that affects a lot of people. The company’s lead...
2022-04-3052 min
The Best Of BioTech IQHow Is Translational Genomics Reducing Background Noise In Multi-Disease Detection? With Aiguo "Adam" ZhangSome of the main problems with sequencing in identifying mutations are its cost and the time it takes. Fortunately, with the rapid growth of technology, revolutionary products that simplify processes are being made. One of those is from DiaCarta, a diagnostics company using translational genomics and molecular precision technology to develop ways of detecting disease. In this episode of BioTech IQ, Ammon Rivera interviews its CEO, Adam Zhang. Their patented technology reduces the "background noise" in testing, allowing for the detection of the "bad actor." Join in to learn the processes behind their work, what this means to the future o...
2022-04-1540 min
The Best Of BioTech IQAddressing One Of The World’s Biggest Drivers Of Disease: Inflammation With Jim Woody, M.D., Ph.D. - CEO 180 Life SciencesTNF is a protein that contributes to inflammation. Anti-TNFs can be used to stabilize this and stop the inflammation. It’s used for diseases like arthritis and psoriasis. Discover how clinical trials are done so these medicines and anti-TNFs can be utilized. Join Ammon Rivera as he talks to M.D., Ph.D. and CEO of 180 Life Sciences, Jim Woody about anti-TNFs and the trial process behind them. Jim’s goal is to address one of the biggest drivers of disease – inflammation. Learn more about Jim’s career as a venture capitalist. Find out why trials need to be uniform and randomi...
2022-04-0146 min
The Best Of BioTech IQ#35 Can Biomea Change the World with Irreversible Drugs and Covalent Bonds? Thomas Butler, CEO - Biomea FusionTom shares with us some of his journey and how that led him to co-found Biomea Fusion. We discuss some of the science behind irreversible drugs and covalent bonding. Using their fusion system there is greater potential for high selectivity, deep inactivation of target, and a greater therapeutic window.https://biomeafusion.com/https://thebiotechiqpodcast.com/podcast/
2022-01-041h 04
The Best Of BioTech IQ#33 Reducing friction at Clinical Trial Start-Up - Sam Searcy, CEO of CliniStartCliniStart launched to provide innovative tech-enabled solutions focused on global investigator contracts, budgets, and payments. And they did all of this just as the COVID-19 pandemic was hitting. This gave them an opportunity to shift and adapt. In this episode we address the challenges causing friction at during clinical trial start-up and what it takes to launch a start-up company.https://clinistart.com/
2021-12-1853 min
The Best Of BioTech IQ#32 People, the most valuable asset a business has. Brenda Sousa - Chief HR OfficerOn this episode we have Brenda Sousa, previously the Chief Human Resources Officer with Constellation Pharmaceuticals. Brenda shares with us part of her backstory and entry into the world of Biotech. We discuss people, culture, the function of HR, and how the industry requires a unique yet similar approach. Ammon also shares past experiences with Brenda and gets her take on them.#BiotechIQ #Biotech #Drugdevelopment #Recruiting #Staffing
2021-12-131h 04The Best Of BioTech IQ#31 Managing CRO relationships and unique business models - Stewart Hallet - COO SFJ PharmaceuticalsIn this episode of BioTech IQ Ammon interviews Stewart Hallet the COO of SFJ Pharmaceuticals, a specialty pharmaceutical company with a unique business model. The discussion touches on a number of things in clinical operations including working with CROs, leadership, and resourcing. #BioTechIQ #ClinicalOperations #DrugDevelopment #Podcasts
2021-11-241h 04
The Best Of BioTech IQ#30 Brazen Bio Part II - Live and In Person!Co-founders Shawn Carbonell and Brent Witgen discuss the progress of the 1st cohort (BRZN1) as they are well into the Brazen Bio program. We also get the chance to interview one of the founders currently in the program. We discuss what he is working on and what his experience has been in the program. Do you have a project that needs acceleration? Then don't hesitate, go to brazen.bio and get your application in for the next cohort.
2021-11-0440 minThe Best Of BioTech IQ#29 Why do we resist? Applying clinical psychology to clinical trials. Kathleen Starr, PhD - EVP Behavioral Insights, Syneos HealthKathleen shares fantastic insights on understanding behavioral psychology and how it applies to successful clinical trials. We had a great conversation that touched on increasing diversity in trials to understanding our own behavior and how we can potentially understand patients better. This can be applied in a way to close the gap between intention and action. Kathleen co-authored a Book called "Why We Resist: The Surprising Truths about Behavior Change: A Guidebook for Healthcare Communicators, Advocates and Change Agents" You can check it out at the link below. PSA: I have no sponsorships or financial agreements to promote the book...
2021-10-2957 minThe Best Of BioTech IQ#28 Vaccine Durability, Diversified Pipeline, Winning Strategy - Seth Lederman, MD - CEO Tonix PharmaceuticalsSeth Lederman is the CEO of Tonix Pharmaceuticals and a physician scientist with a two decades of research experience. Prior to becoming an entrepreneur, he was an Associate Professor at Columbia University. Dr. Lederman’s groundbreaking research led to the discovery of the CD-40 ligand and its role in T cell helper function. Currently, Dr. Lederman oversees Tonix Pharmaceuticals and its diverse programs that are aimed to develop therapeutics for chronic CNS and immunologic conditions, that include indications like fibromyalgia, Covid-19 and Long Covid, amongst others. Dr. Lederman earned an AB from Princeton University in Chemistry and an MD from Co...
2021-10-0156 minThe Best Of BioTech IQ#27 How do you effectively manage the CMC process? With Doug Looker, PhDDoug Looker is the VP of Operations with Validus Cellular Therapeutics. Validus is using cellular therapy to target infections by fighting the biology of antimicrobial resistance by activating the biology of the mammalian immune system. Doug walks us the through the process of establishing the CMC process that will drive success at every stage of the clinical trial process. And we have a brief discussion on animals being used in trials.During the recording and editing of this episode Doug was the VP of Preclinical Development and Manufacturing at Amicrobe, Inc. Therefore the intro does not reflect his...
2021-09-2129 min